Inflammatix raises $32M, plus a BARDA contract, for its point-of-care infection diagnostics

money
Inflammatix's new financing follows a $72 million contract with the U.S. Biomedical Advanced Research and Development Authority to develop its tests for acute infections and sepsis. (Getty Images)

Inflammatix, maker of an immune system-focused molecular diagnostic test, has secured $32 million in funding to power its commercial launches in Europe and regulatory submissions for the FDA. 

The company’s series C round included previous backers Khosla Ventures, Northpond Ventures and Think.Health Ventures as well as new investor Grey Sky Venture Partners.

The new financing follows a November 2019 contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop its tests for acute infections and sepsis. The BARDA cost-sharing contract includes up to $72 million based on certain milestones.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"We are pleased to have the support of this strong group of healthcare investors who share our excitement about leveraging the immune response to build novel precision diagnostics for infectious and inflammatory disease,” Inflammatix co-founder and CEO Tim Sweeney said in a statement

“In particular, our first tests will help tackle antibiotic resistance and sepsis, two critical public health challenges, by reading the patient's host-immune response to infection," Sweeney added. "With this financing in hand, we look forward to bringing our rapid HostDx tests into hospitals and clinics so that physicians can quickly get the right treatments to the right patients."

Inflammatix's tests use machine learning algorithms to parse the expression of multiple immune system genes that make up the host response, in order to identify the presence of a bacterial or viral infection and determine if a patient is likely to develop sepsis.

It is designed to produce point-of-care results in 30 minutes or less. The company said it plans to submit its tests for FDA review in 2021.

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.